Biogen gains as pipeline updates and fresh Street target hikes buoy sentiment

Biogen (BIIB) is up 3.1% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied to a combination of favorable recent company updates and improving sentiment around Biogen’s growth portfolio. New clinical disclosures tied to zorevunersen, added reimbursement support for LEQEMBI in Canada, and fresh price-target increases from Wall Street firms likely helped keep buyers engaged.

Details:

Biogen and Stoke Therapeutics announced new presentations of long-term zorevunersen data for Dravet syndrome on September 1, highlighting durable seizure reduction, sustained cognition and behavior improvements, and a generally well-tolerated safety profile.

The same release noted that enrollment in the Phase 3 EMPEROR study of zorevunersen has been completed, giving investors another visible late-stage development milestone.

On August 31, Biogen said Canada’s drug agency issued a final positive recommendation supporting public reimbursement of LEQEMBI for eligible patients with early Alzheimer’s disease, which can be viewed as supportive for the product’s commercial outlook.

Investor sentiment also appears to have been helped by research-note summaries showing higher price targets from Piper Sandler and TD Cowen, as the market continues to focus on LEQEMBI uptake and Biogen’s transition toward newer growth assets.

Sources:

Biogen, Stoke Therapeutics, Investing.com

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$BIIB Insider Trading Activity

$BIIB insiders have traded $BIIB stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.

Here’s a breakdown of recent trading of $BIIB stock by insiders over the last 6 months:

LLOYD MINOR has made 0 purchases and 2 sales selling 1,186 shares for an estimated $239,749.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$BIIB Hedge Fund Activity

We have seen 550 institutional investors add shares of $BIIB stock to their portfolio, and 458 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

FMR LLC added 5,409,698 shares (+42.2%) to their portfolio in Q2 2026, for an estimated $1,168,819,349
JPMORGAN CHASE & CO added 1,823,140 shares (+inf%) to their portfolio in Q2 2026, for an estimated $393,907,628
PACER ADVISORS, INC. added 1,122,981 shares (+inf%) to their portfolio in Q2 2026, for an estimated $242,631,274
SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 1,117,663 shares (+inf%) to their portfolio in Q2 2026, for an estimated $241,482,267
VAN ECK ASSOCIATES CORP removed 981,752 shares (-90.9%) from their portfolio in Q2 2026, for an estimated $212,117,337
POINT72 ASSET MANAGEMENT, L.P. removed 721,468 shares (-89.1%) from their portfolio in Q2 2026, for an estimated $155,880,376
T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 664,588 shares (-85.4%) from their portfolio in Q2 2026, for an estimated $143,590,883

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$BIIB Congressional Stock Trading

Members of Congress have traded $BIIB stock 7 times in the past 6 months. Of those trades, 5 have been purchases and 2 have been sales.

Here’s a breakdown of recent trading of $BIIB stock by members of Congress over the last 6 months:

REPRESENTATIVE KEVIN HERN sold up to $15,000 on 08/18.
REPRESENTATIVE GILBERT RAY CISNEROS, JR. purchased up to $15,000 on 06/05.
REPRESENTATIVE MARIA ELVIRA SALAZAR has traded it 4 times. They made 3 purchases worth up to $130,000 on 05/12, 05/11 and 1 sale worth up to $50,000 on 06/02.
SENATOR ALAN ARMSTRONG purchased up to $15,000 on 03/27.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$BIIB Analyst Ratings

Wall Street analysts have issued reports on $BIIB in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Needham issued a "Buy" rating on 06/29/2026
Evercore ISI Group issued a "Outperform" rating on 05/15/2026
Guggenheim issued a "Buy" rating on 04/30/2026

To track analyst ratings and price targets for $BIIB, check out Quiver Quantitative's $BIIB forecast page.

$BIIB Price Targets

Multiple analysts have issued price targets for $BIIB recently. We have seen 15 analysts offer price targets for $BIIB in the last 6 months, with a median target of $225.0.

Here are some recent targets:

Matthew Harrison from Morgan Stanley set a target price of $222.0 on 07/08/2026
Brian Abrahams from RBC Capital set a target price of $242.0 on 07/07/2026
Ami Fadia from Needham set a target price of $256.0 on 06/29/2026
Salim Syed from Mizuho set a target price of $221.0 on 06/15/2026
David Amsellem from Piper Sandler set a target price of $225.0 on 05/15/2026
Geoff Meacham from Citigroup set a target price of $200.0 on 05/01/2026
Yatin Suneja from Guggenheim set a target price of $260.0 on 04/30/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.